Last reviewed · How we verify
Chemotherapy（carboplatin）
Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cancer cell replication and inducing apoptosis.
Carboplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing cancer cell replication and inducing apoptosis. Used for Lung cancer (phase 3 trial context), Ovarian cancer, Breast cancer.
At a glance
| Generic name | Chemotherapy（carboplatin） |
|---|---|
| Also known as | carboplatin |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Carboplatin binds to DNA and forms interstrand and intrastrand crosslinks, disrupting DNA synthesis and repair mechanisms. This leads to cell cycle arrest and programmed cell death in rapidly dividing cancer cells. It is a second-generation platinum compound with a more favorable toxicity profile compared to cisplatin.
Approved indications
- Lung cancer (phase 3 trial context)
- Ovarian cancer
- Breast cancer
- Head and neck cancer
Common side effects
- Thrombocytopenia
- Neutropenia
- Anemia
- Nausea and vomiting
- Nephrotoxicity
- Ototoxicity
- Peripheral neuropathy
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chemotherapy（carboplatin） CI brief — competitive landscape report
- Chemotherapy（carboplatin） updates RSS · CI watch RSS
- Shanghai Pulmonary Hospital, Shanghai, China portfolio CI